Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Den Boer group

The Den Boer group focuses on the discovery of new (genetic) lesions and targets for precision medicines to improve the clinical outcome for children with acute lymphoblastic leukemia. We have expertise in so-called pathobiological studies addressing which (combination of) genetic lesions characterize the patients’ leukemia, how these lesions functionally contribute to therapy resistance and how these lesions affect the interaction of leukemic cells with the bone marrow microenvironment. This information is essential to develop strategies that kill leukemic cells more specifically.

PI: Prof.dr. Monique L. den Boer


"Leukemia cannot be prevented, so let’s beat the leukemic cells at their Achilles’ heel." Prof.dr. Monique den Boer - PI


Main topics of studies:


Applications for scientific internships (MD, MSc, HLO) can be directed to m.l.denboer@prinsesmaximacentrum.nl

Den Boer group